Scholarlink

Hospital-based boron neutron capture therapy (BNCT) devices have been developed and are becoming more popular. Currently, BNCT is primarily indicated for locally recurrent advanced or refractory head and neck cancer and brain tumors. Successful BNCT requires selective tumor uptake of 4-10B-borono-L-phenylalanine (10B-BPA), and positron emission tomography (PET) can predict the level of 10B-BPA in tissues by using 10B-borono-2-18F-fluoro-L-phenylalanine (18F-FBPA). In this chapter, we summarize the basic studies and clinical research findings to date on 18F-FBPA PET for BNCT. In the future, the close relationship between BNCT and 18F-FBPA PET can be expected to improve the treatment accuracy of BNCT and expand the indications for BNCT.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Boron Imaging: Macroscopic—PET

  • 章节

  • 发表日期：

    2025年

查看全文
  • Kayako Isohashi,
  • Jun Hatazawa,
  • Koji Ono

摘要

Hospital-based boron neutron capture therapy (BNCT) devices have been developed and are becoming more popular. Currently, BNCT is primarily indicated for locally recurrent advanced or refractory head and neck cancer and brain tumors. Successful BNCT requires selective tumor uptake of 4-10B-borono-L-phenylalanine (10B-BPA), and positron emission tomography (PET) can predict the level of 10B-BPA in tissues by using 10B-borono-2-18F-fluoro-L-phenylalanine (18F-FBPA). In this chapter, we summarize the basic studies and clinical research findings to date on 18F-FBPA PET for BNCT. In the future, the close relationship between BNCT and 18F-FBPA PET can be expected to improve the treatment accuracy of BNCT and expand the indications for BNCT.